Clinical Trials Logo

Primary Glioblastoma clinical trials

View clinical trials related to Primary Glioblastoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05318612 Active, not recruiting - Clinical trials for Primary Glioblastoma

Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)

EMITT
Start date: April 8, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to investigate the (cost-)effectiveness of LITT (Laser Interstitial Thermal Therapy) in primary irresectable glioblastoma. Glioblastoma are the most common malignant brain tumors and are, due to their devastating nature and the fact that these tumors occur at a relatively young age (median 59 years), responsible for up to 7% of total life years lost from cancer before the age of 70. The current treatment of glioblastoma consists of maximal safe surgery combined with adjuvant chemoradiation therapy (CRT). However, despite this aggressive treatment, these patients still face a poor prognosis (median overall survival 14.5 - 18.5 months). In addition to that, around 30% of the patients diagnosed with a glioblastoma are not suitable for surgery. These patients miss the benefit of a resection and face an even worse prognosis (median overall survival 5.1 months). The primary aim of this project is to investigate whether laser therapy combined with CRT improves overall survival, without compromising quality of life, in comparison with CRT alone in patients with primary irresectable glioblastoma.

NCT ID: NCT04250922 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

LAM561 With RT and TMZ for Adults With Glioblastoma

CLINGLIO
Start date: December 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.